Get all your news in one place.

100’s of premium titles.
One app.

Get all your news in one place.

100’s of premium titles. One news app.

The Latest Breaking News from Eli Lilly And Co

Eli Lilly To Suspend Sale Of 'Non-Essential' Medicines To Russia

Eli Lilly And Co (NYSE: LLY) said it would continue to supply drugs to Russia for urgent medical conditions such as cancer and diabetes but will suspend sales of "non-essential medicines."

Eli Lilly's JAK Inhibitor Baricitinib Cuts Death Risk By 13% In COVID-19 Patients

Eli Lilly's JAK Inhibitor Baricitinib Cuts Death Risk By 13% In COVID-19 Patients

According to a British study, Eli Lilly And Co (NYSE:LLY) and Incyte Corporation's (NASDAQ:INCY) Olumiant (baricitinib) reduced the risk of death in hospitalized COVID-19 patients by 13%. According to a Reuters report, more than 8,000 patients were administered baricitinib in addition to standard of care in the RECOVERY Trial. Results showed that 546 patients…

FDA Approves Eli Lilly's Jardiance In Broader Heart Patient Population

FDA Approves Eli Lilly's Jardiance In Broader Heart Patient Population

The FDA approved Eli Lilly And Co (NYSE:LLY) and partner Boehringer Ingelheim's drug, Jardiance, for expanded use in reducing the risk of death and hospitalization for all patients with heart failure. Initially approved by the FDA in 2014 for type 2 diabetes patients, the drug's use was expanded last year in some adults living with heart failure…

From analysis to the latest developments in health,
read the most diverse news in one place.

inkl

Eli Lilly Bets On RNA Potential With $700M Investment In Boston's Seaport

Eli Lilly And Co (NYSE: LLY)

Nearly 66% Of Patients Respond To Eli Lilly's Mirikizumab In Ulcerative Colitis Study

Patients with moderately-to-severely active ulcerative colitis (UC) who took Eli Lilly And Co's (NYSE: LLY) mirikizumab

ICER's Report Suggests Benefits Of Eli Lilly's Tirzepatide Not Better Than Other Diabetes Drugs

Institute for Clinical and Economic Review (ICER) casts doubts on Eli Lilly And Co’s (NYSE: LLY) tirzepatide, a type II diabetes candidate, about its usefulness to patients compared to the rivals.

FDA AdComm Votes Against Lilly's Lung Cancer Drug, Sintilimab

The FDA advisory committee voted against the full approval of Eli Lilly And Co's (NYSE: LLY) lung cancer treatment over concerns that the clinical trial was conducted only in China and that its results did not apply to U.S. patients.

inkl

Read news from The Economist, FT, and more,
with one subscription

Eli Lilly Q4 Earnings Beat Estimates On Higher Demand For Trulicity, COVID-19 Therapies; Reaffirms FY22 Guidance

Eli Lilly Q4 Earnings Beat Estimates On Higher Demand For Trulicity, COVID-19 Therapies; Reaffirms FY22 Guidance

Eli Lilly And Co (NYSE: LLY) has

Lilly To Inject $1B In New Manufacturing Facility In North Carolina, US

Lilly To Inject $1B In New Manufacturing Facility In North Carolina, US

Eli Lilly And Co (NYSE: LLY)

Eli Lilly Plans To Invest €400M In Manufacturing Facility In Ireland: Report

Eli Lilly Plans To Invest €400M In Manufacturing Facility In Ireland: Report

Eli Lilly And Co (NYSE: LLY) plans to invest more than €400 million into a new manufacturing facility in Limerick, Ireland, according to a

Eli Lilly Expects FDA Rejection For Expanded Use Baricitinib For Eczema

Eli Lilly Expects FDA Rejection For Expanded Use Baricitinib For Eczema

Based on top-line efficacy results from two pivotal Phase 3 trials Eli Lilly And Co (NYSE: LLY) has decided to

FDA Rescinds Authorization For Regeneron, Eli Lilly COVID-19 Antibody Treatments: Here's Why

FDA Rescinds Authorization For Regeneron, Eli Lilly COVID-19 Antibody Treatments: Here's Why

Antibody treatments made by Regeneron Pharmaceuticals Inc (NASDAQ: REGN) and Eli Lilly And Co (NYSE: LLY) are not likely to work against the Omicron variant of COVID-19 and their emergency use authorization has been rescin

Abbisko, Lilly Ink Licensing Pact For Cardiometabolic Diseases

Abbisko, Lilly Ink Licensing Pact For Cardiometabolic Diseases

Abbisko Therapeutics has entered into a worldwide collaboration and exclusive licensing agreement with Eli Lilly And Co (NYSE: LLY) for novel molecules against an

People

From analysis to the latest developments in health,
read the most diverse news in one place.

inkl

Organisations

Regeneron Pharmaceuticals Inc

Eli Lilly And Co

Incyte Corporation

Boehringer Ingelheim

inkl

Read news from The Economist, FT, and more,
with one subscription

Topics

Places

290,234 stories

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.

Download on the AppStore

Get it on Google Play